BACKGROUND AND OBJECTIVE: The association of large arterial rigidity and kidney function decline in longitudinal analyses is not well established. This study evaluated the association of aortic pulse wave velocity (aPWV) and pulse pressure (PP) with rapid kidney function decline and incident CKD in the Health, Aging and Body Composition study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants were 2129 older adults with a baseline measurement of aPWV, PP, and cystatin C and at least one additional measurement of cystatin C, either at year 3 or year 10. Outcomes were rapid kidney function decline (estimated GFRcysC loss of >3 ml/min per 1.73 m(2) per year) and incident CKD (eGFRcysC < 60 ml/min per 1.73 m(2) in participants with baseline estimated GFR > 60 ml/min per 1.73 m(2)). Multivariate regression models were used to evaluate association of aPWV and PP with each outcome. RESULTS: Mean (SD) baseline estimated GFRcysC was 79±29 ml/min per 1.73 m(2). Median follow-up duration was 8.9 years. In multivariable analyses, aPWV was not associated with rapid decline (odds ratio [OR], 95% confidence interval [CI] 1.16, 0.89-1.52) but was associated with incident CKD (incident rate ratio [IRR], 95% CI, 1.39, 1.09-1.77) and PP was associated with both rapid decline (OR, 95% CI 1.10, 1.04-1.16) and incident CKD (IRR, 95% CI, 1.06, 1.01-1.11). CONCLUSIONS: Large arterial stiffness assessed by aPWV and pulsatility assessed by PP were associated with incident CKD among older adults. Pulsatility assessed by PP was associated with rapid kidney function decline and incident CKD. Future research should determine whether interventions targeting arterial rigidity will prevent CKD development and progression.
BACKGROUND AND OBJECTIVE: The association of large arterial rigidity and kidney function decline in longitudinal analyses is not well established. This study evaluated the association of aortic pulse wave velocity (aPWV) and pulse pressure (PP) with rapid kidney function decline and incident CKD in the Health, Aging and Body Composition study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants were 2129 older adults with a baseline measurement of aPWV, PP, and cystatin C and at least one additional measurement of cystatin C, either at year 3 or year 10. Outcomes were rapid kidney function decline (estimated GFRcysC loss of >3 ml/min per 1.73 m(2) per year) and incident CKD (eGFRcysC < 60 ml/min per 1.73 m(2) in participants with baseline estimated GFR > 60 ml/min per 1.73 m(2)). Multivariate regression models were used to evaluate association of aPWV and PP with each outcome. RESULTS: Mean (SD) baseline estimated GFRcysC was 79±29 ml/min per 1.73 m(2). Median follow-up duration was 8.9 years. In multivariable analyses, aPWV was not associated with rapid decline (odds ratio [OR], 95% confidence interval [CI] 1.16, 0.89-1.52) but was associated with incident CKD (incident rate ratio [IRR], 95% CI, 1.39, 1.09-1.77) and PP was associated with both rapid decline (OR, 95% CI 1.10, 1.04-1.16) and incident CKD (IRR, 95% CI, 1.06, 1.01-1.11). CONCLUSIONS: Large arterial stiffness assessed by aPWV and pulsatility assessed by PP were associated with incident CKD among older adults. Pulsatility assessed by PP was associated with rapid kidney function decline and incident CKD. Future research should determine whether interventions targeting arterial rigidity will prevent CKD development and progression.
Authors: Carmen A Peralta; David R Jacobs; Ronit Katz; Joachim H Ix; Magdalena Madero; Daniel A Duprez; Mark J Sarnak; Michael H Criqui; Holly J Kramer; Walter Palmas; David Herrington; Michael G Shlipak Journal: Am J Kidney Dis Date: 2011-10-14 Impact factor: 8.860
Authors: Jacques Blacher; Michel E Safar; Alain P Guerin; Bruno Pannier; Sylvain J Marchais; Gérard M London Journal: Kidney Int Date: 2003-05 Impact factor: 10.612
Authors: Preston S Klassen; Edmund G Lowrie; Donal N Reddan; Elizabeth R DeLong; Joseph A Coladonato; Lynda A Szczech; J Michael Lazarus; William F Owen Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: Mark J Sarnak; Ronit Katz; Catherine O Stehman-Breen; Linda F Fried; Nancy Swords Jenny; Bruce M Psaty; Anne B Newman; David Siscovick; Michael G Shlipak Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Katherine H Michener; Gary F Mitchell; Farzad Noubary; Naya Huang; Tamara Harris; Margret B Andresdottir; Runolfur Palsson; Vilmundur Gudnason; Andrew S Levey Journal: Am J Nephrol Date: 2015-06-06 Impact factor: 3.754
Authors: K P Ng; W E Moody; C D Chue; N C Edwards; T Savage; C R V Tomson; R P Steeds; J N Townend; C J Ferro Journal: J Hum Hypertens Date: 2013-08-01 Impact factor: 3.012
Authors: Jennifer G Naples; Zachary A Marcum; Subashan Perera; Anne B Newman; Susan L Greenspan; Shelly L Gray; Douglas C Bauer; Eleanor M Simonsick; Ronald I Shorr; Joseph T Hanlon Journal: Drugs Aging Date: 2016-06 Impact factor: 3.923
Authors: Sanaz Sedaghat; Francesco U S Mattace-Raso; Ewout J Hoorn; Andre G Uitterlinden; Albert Hofman; M Arfan Ikram; Oscar H Franco; Abbas Dehghan Journal: Clin J Am Soc Nephrol Date: 2015-11-12 Impact factor: 8.237